Schrödinger, Inc. (SDGR) 股票分析

公司概述

Schrödinger, Inc. operates within the healthcare sector, specifically focusing on the health information services industry, where it develops a physics-based computational platform to facilitate the discovery of novel molecules for drug development and materials applications across global regions including the United States, Asia-Pacific, Europe, the Middle East, Africa, and international markets. The company's market capitalization stands at $848.99 million, supported by an annual trailing twelve-month revenue of $255.87 million and an employed workforce of 850 individuals. These valuation and revenue figures position the entity as a mid-cap player with significant operational scale, yet the negative revenue growth trajectory suggests the company is currently facing headwinds in expanding its top-line performance. While the market cap indicates substantial investor interest, the combination of declining revenue and a negative operating margin highlights the intense capital expenditure and cost pressures inherent in the computational biology and drug discovery sectors.

财务健康

Schrödinger, Inc. reported a net income of -$103,265,000 for the trailing twelve months, while generating $255.87 million in revenue and an EBITDA of -$160,874,000, revealing a significant gap between gross revenue generation and bottom-line profitability that points to substantial operating expenses or non-operating losses. Despite the negative net income and EBITDA, the company maintains a robust free cash flow of $99.98 million, which provides critical financial flexibility to fund ongoing R&D initiatives, manage capital expenditures, and potentially reduce debt without immediate reliance on external equity financing. The company's margin profile shows a gross margin of 55.7%, indicating strong pricing power or low cost of goods sold relative to revenue, while the operating margin sits at -19.7% and the profit margin at -40.4%, reflecting high fixed costs and significant non-operating charges that erode overall profitability. On the liability side, the company holds $395.46 million in cash against $109.31 million in debt, resulting in a debt-to-equity ratio of 30.03, which suggests a leveraged balance sheet where equity capital is relatively small compared to total debt obligations. However, the current ratio of 2.75 indicates a strong short-term liquidity position, as current assets are more than double the current liabilities, ensuring the ability to meet short-term obligations comfortably. Furthermore, the return on equity is -26.3% and the return on assets is -13.5%, metrics that reveal that management effectiveness in generating returns on shareholder and asset bases has been negative during this period, likely driven by the investment-heavy nature of the business model and current earnings deficits.

估值评估

The valuation metrics for Schrödinger, Inc. present a complex picture, with a trailing twelve-month P/E ratio listed as N/A due to negative earnings, and a forward P/E ratio of -8.33, which implies that the market is pricing in a future recovery of earnings or is currently discounting the stock heavily based on expected turnaround timelines. The price-to-book ratio is 2.33, suggesting that the market values the company at a 133% premium over its net book value, which could reflect intangible assets, proprietary technology, or future growth potential not captured on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 3.32 and an EV/EBITDA of -3.50 further indicate that traditional earnings-based valuation models are not applicable, forcing reliance on revenue-based or enterprise value metrics that emphasize top-line growth potential despite current losses. The stock's price has fluctuated significantly over the past year, trading between a 52-week high of $27.63 and a 52-week low of $10.95, illustrating the high degree of price volatility associated with the company's uncertain earnings outlook. With a beta of 1.62, the stock exhibits price volatility that is significantly higher than the broader market, meaning that for every 1% move in the market, SDGR is expected to move approximately 1.62%, amplifying both potential gains and losses for risk-tolerant investors.

Growth & Income

The company's financial trajectory shows a revenue growth year-over-year of -1.2%, while earnings growth is N/A due to the absence of positive prior-period earnings, implying that the business is currently in a contractionary phase regarding top-line expansion rather than a period of profitable scaling. As a non-dividend payer, Schrödinger, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all of its earnings to reinvest into research and development, computational platform expansion, and organic growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology and computational science firms in the growth phase, where capital allocation prioritizes long-term technological leadership over immediate shareholder returns. Consequently, the overall growth and income profile for Schrödinger, Inc. is characterized by negative revenue momentum, a complete absence of dividend income, and a reliance on internal cash generation and external financing to sustain operations and fund future innovation cycles.